![ChemicalBook](https://m.chemicalbook.com/Scripts/New/img/logo.png)
![структурированное изображение](/CAS/GIF/610798-31-7.gif)
Icotinib
- русский язык имя
- английское имяIcotinib
- CAS №610798-31-7
- CBNumberCB82616025
- ФормулаC22H21N3O4
- мольный вес391.42
- EINECS1592732-453-0
- номер MDLMFCD22124501
- файл Mol610798-31-7.mol
химическое свойство
Температура кипения | 581℃ |
плотность | 1.31 |
Fp | 305℃ |
температура хранения | Store at -20°C |
растворимость | insoluble in H2O; ≥129.6 mg/mL in DMSO; ≥14.13 mg/mL in EtOH with ultrasonic |
форма | Powder |
пка | 5.32±0.20(Predicted) |
цвет | White to off-white |
FDA UNII | 9G6U5L461Q |
Код УВД | L01EB08 |
рисовальное письмо(GHS)
-
рисовальное письмо(GHS)
-
сигнальный язык
предупреждение
-
вредная бумага
H302:Вредно при проглатывании.
-
оператор предупредительных мер
P264:После работы тщательно вымыть кожу.
P270:При использовании продукции не курить, не пить, не принимать пищу.
P301+P312:ПРИ ПРОГЛАТЫВАНИИ: Обратиться за медицинской помощью при плохом самочувствии.
P501:Удалить содержимое/ контейнер на утвержденных станциях утилизации отходов.
Icotinib химические свойства, назначение, производство
Описание
Icotinib is also known as ConMana. It is a highly selective, first-generation inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TKI), whose mutation and overexpression is involved in many kinds of cancer. Icotinib is a quinazoline derivative that binds reversibly to the ATP binding site of the EGFR protein, being capable of blocking the signal transduction cascade. It is currently under investigation for its treatment efficacy on the EGFR+ Non-small cell lung cancer.Использование
Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with IC50 of 5 nM.Показания
Icotinib (Conmana?, BetaPharma), an EGFR inhibitor, was approved by the China State FDA in 2011 for the treatment of NSCLC. Icotinib resembles erlotinib in possessing the N-(3-ethylnylphenyl) quinazolin-4-amine core scaffold of erlotinib that binds to the EGFR ATP pocket. An adjacent hydrophobic group was also retained while the solvent exposed two 2-methoxyethyoxysubstituents at the 6- and 7-positions of the quinazoline core were cyclized to afford the tetraoxacyclododecene moiety of icotinib. Efficacy and safety of icotinib as first-line therapy in patients has been evaluated for advanced NSCLC in recent clinical studies.Общее описание
Class: receptor tyrosine kinaseTreatment: NSCLC
Oral bioavailability = 52%
Elimination half-life = 5.5 h
использованная литература
Tan, F., et al. "Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. " Lung Cancer76.2(2012):177-82.Shi, Y., et al. "Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial." Lancet Oncology 14.10(2013):953-61.
Sun, Y., Y. Shi, and L. Zhang. "A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN)."Journal of Thoracic Oncology 29.15(2011):-.
https://en.wikipedia.org/wiki/Icotinib
Icotinib поставщик
поставщик | телефон | страна | номенклатура продукции | благоприятные условия |
---|---|---|---|---|
571-85586718 +8613336195806 |
China | 29798 | 60 | |
+86-0371-86658258 +8613203830695 |
China | 29889 | 58 | |
86-13657291602 | CHINA | 22968 | 58 | |
+1-631-485-4226 | United States | 19553 | 58 | |
+86-023-6139-8061 +86-86-13650506873 |
China | 39916 | 58 | |
+86-29-89586680 +86-15129568250 |
China | 24295 | 58 | |
+86-27-87465837 +8618971612321 |
China | 9641 | 58 | |
0917-3909592 13892490616 |
China | 9319 | 58 | |
+1-2135480471 +1-2135480471 |
China | 10522 | 58 | |
+1-708-310-1919 +1-13798911105 |
United States | 6393 | 58 |